4.6 Article

Machine learning-based prediction of cognitive outcomes in de novo Parkinson's disease

期刊

NPJ PARKINSONS DISEASE
卷 8, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41531-022-00409-5

关键词

-

资金

  1. ZonMw Memorabel Grant [733050516]
  2. Medical Research Council [MR/S011625/1]
  3. Charles Wolfson Charitable Trust
  4. BRACE Dementia Research
  5. Michael J. Fox Foundation for Parkinson's Research
  6. 4D Pharma
  7. AbbVie
  8. AcureX Therapeutics
  9. Allergan
  10. Amathus Therapeutics
  11. Aligning Science Across Parkinson's (ASAP)
  12. Avid Radiopharmaceuticals
  13. Bial Biotech
  14. Biogen
  15. BioLegend
  16. Bristol Myers Squibb
  17. Calico Life Sciences LLC
  18. Celgene Corporation
  19. DaCapo Brainscience
  20. Denali Therapeutics
  21. Edmond J. Safra Foundation
  22. Eli Lilly and Company
  23. GE Healthcare
  24. GlaxoSmithKline
  25. Golub Capital
  26. Handl Therapeutics
  27. Insitro
  28. Janssen Pharmaceuticals
  29. Lundbeck
  30. Merck Co.
  31. Meso Scale Diagnostics LLC
  32. Neurocrine Biosciences
  33. Pfizer
  34. Piramal Imaging
  35. Prevail Therapeutics
  36. F. Hoffmann-La Roche
  37. Genentech
  38. Sanofi Genzyme
  39. Servier
  40. Takeda Pharmaceutical Company
  41. Teva Neuroscience
  42. UCB
  43. Vanqua Bio
  44. Verily Life Sciences
  45. Voyager Therapeutics
  46. Yumanity Therapeutics
  47. University of Exeter

向作者/读者索取更多资源

This study aimed to predict cognitive outcomes in Parkinson's disease patients using machine learning models. The research found that clinical variables performed best in predicting cognitive impairment outcomes, and including biofluid and genetic/epigenetic variables slightly improved prediction performance.
Cognitive impairment is a debilitating symptom in Parkinson's disease (PD). We aimed to establish an accurate multivariate machine learning (ML) model to predict cognitive outcome in newly diagnosed PD cases from the Parkinson's Progression Markers Initiative (PPMI). Annual cognitive assessments over an 8-year time span were used to define two cognitive outcomes of (i) cognitive impairment, and (ii) dementia conversion. Selected baseline variables were organized into three subsets of clinical, biofluid and genetic/epigenetic measures and tested using four different ML algorithms. Irrespective of the ML algorithm used, the models consisting of the clinical variables performed best and showed better prediction of cognitive impairment outcome over dementia conversion. We observed a marginal improvement in the prediction performance when clinical, biofluid, and epigenetic/genetic variables were all included in one model. Several cerebrospinal fluid measures and an epigenetic marker showed high predictive weighting in multiple models when included alongside clinical variables.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据